Vivani Posts $7.3M Q3 Loss, Confirms SLIM-1 Implant Data Due This Week
VANI sits 22% above its 52-week low of $0.923.
Summary
Vivani reported a Q3 2026 net loss of $7.3 million, wider than the $6.5 million loss a year earlier, with R&D up 11% to $5.0 million and G&A up 14% to $2.5 million. Cash, cash equivalents and restricted cash fell to $15.5 million from $20.8 million at June 30, continuing the going-concern squeeze flagged in the August 10-Q. The real driver is the timing: top-line SLIM-1 Phase 1 data for NPM-139, the once- or twice-yearly semaglutide implant, is now expected later this week, consistent with the October investor deck's November 2026 target. The Cortigent-ClearOne merger remains stuck awaiting final regulatory approval after missing its October close, with ClearOne still pursuing a $10-15 million raise at closing. SLIM-1 results this week are the binary event for the stock; the merger approval is the second trigger.
At the time of this announcement, VANI was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101.9M. The 52-week trading range was $0.92 to $1.66. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.